When I search for investment opportunities, it's rare for an old article to capture my attention. Yet, an article from The Wall Street Journal in January titled "Americans Can't Stop Pampering Their Pets - Companies Want In" has lingered in my thoughts. While the sentiment of treating pets as family isn't new, the financial implications
Global Market Comments October 12, 2023 Fiat Lux Featured Trade: (MONDAY, OCTOBER 30 SARASOTA, FLORIDA GENERAL JAMES MATTIS STRATEGY LUNCHEON) (WHY TECHNICAL ANALYSIS DIS A DISASTER) (SPY), (QQQ), (IWM), (VIX), (TESTIMONIAL)
(PLANT EXTINCTIONS COULD THREATEN THE CREATION OF MEDICINES) October 11, 2023 Hello everyone, Welcome to a future world with far less plant variety. Dr Brown is one of the researchers who works at the Royal Botanic Gardens, Kew, who, along with others, has recently published a new report called State of the World’s
Mad Hedge Technology Letter October 11, 2023 Fiat Lux Featured Trade: (QUESTIONS POP UP ABOUT GENERATIVE AI) (GOOGL), (AI)
Google is worried that generative artificial intelligence isn’t as accurate or as useful as currently advertised. There have been major disagreements among internal Google engineers about whether this service is additive at all. Google product managers, designers, and engineers have used a chat forum to openly debate the AI tool's effectiveness and utility, with some
Global Market Comments October 11, 2023 Fiat Lux Featured Trade: (FRIDAY, OCTOBER 20 LONDON, ENGLAND GLOBAL STRATEGY LUNCHEON) (THE HARD TRUTH BEHIND BUYING IN NOVEMBER), (NOTICE TO MILITARY SUBSCRIBERS)
Come join me for lunch for the Mad Hedge Fund Trader’s Global Strategy Update, which I will be conducting in London at 12:30 PM on Friday, October 20, 2023. A three-course lunch is included. I’ll be giving you my up-to-date view on stocks, bonds, currencies commodities, precious metals, and real estate. And to keep
Mad Hedge Biotech and Healthcare Letter October 10, 2023 Fiat Lux Featured Trade: (FROM MEMORY LAPSES TO MARKET LEAPS) (BIIB), (ESAIY), (SAGE)
In the intricate maze of Alzheimer's disease (AD) research, many pharmaceutical pioneers have found themselves at dead ends. Over the past decades, the quest for groundbreaking AD treatments has seen numerous experimental drugs falter. Yet, against this backdrop, Biogen (BIIB) stands out, having secured approvals for two AD drugs within a span of just a
Global Market Comments October 10, 2023 Fiat Lux Featured Trade: (FRIDAY, OCTOBER 13 KIEV, UKRAINE GLOBAL STRATEGY LUNCHEON) (WILL SPACEX BE YOUR NEXT TEN BAGGER?) (EBAY), (TSLA), (SCTY), (BA), (LMT)